Clinical Trial Update: Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of cobimetinib plus atezolizumab and hydroxychloroquine in KRAS-mutated advanced gastrointestinal cancers was terminated, with results posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Columbia University | Conditions: Gastrointestinal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-12-18